Skip to main content

CombiMatrix Taps Prisma Biotech to Market, Sell CustomArrays in Taiwan, China

NEW YORK, April 28 (GenomeWeb News) - CombiMatrix today said that Prisma Biotech will promote and sell its products in Taiwan, China, and "various" other countries.

 

The Acacia unit also said that Prisma "has the ability to synthesize content onto CombiMatrix CustomArrays and to sell those arrays to end customers."

 

Financial terms of the agreement were not disclosed.

 

CombiMatrix is currently establishing manufacturing and distribution relationships with regional companies to "enable them to manufacture arrays onsite for their local markets," the company said. "Such relationships benefit CombiMatrix by expanding the commercial market for its products without having to build additional infrastructure."

 

Besides selling its synthesizers to these partners, CombiMatrix said it "will continue to sell blank CustomArrays, reagents, additional synthesizers, and equipment to the partner for its local customers."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.